EconPapers    
Economics at your fingertips  
 

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo

Christiane Kofink, Nicole Trainor, Barbara Mair, Simon Wöhrle, Melanie Wurm, Nikolai Mischerikow, Michael J. Roy, Gerd Bader, Peter Greb, Géraldine Garavel, Emelyne Diers, Ross McLennan, Claire Whitworth, Vesna Vetma, Klaus Rumpel, Maximilian Scharnweber, Julian E. Fuchs, Thomas Gerstberger, Yunhai Cui, Gabriela Gremel, Paolo Chetta, Stefan Hopf, Nicole Budano, Joerg Rinnenthal, Gerhard Gmaschitz, Moriz Mayer, Manfred Koegl, Alessio Ciulli, Harald Weinstabl () and William Farnaby ()
Additional contact information
Christiane Kofink: Boehringer Ingelheim RCV GmbH & Co KG
Nicole Trainor: University of Dundee
Barbara Mair: Boehringer Ingelheim RCV GmbH & Co KG
Simon Wöhrle: Boehringer Ingelheim RCV GmbH & Co KG
Melanie Wurm: Boehringer Ingelheim RCV GmbH & Co KG
Nikolai Mischerikow: Boehringer Ingelheim RCV GmbH & Co KG
Michael J. Roy: University of Dundee
Gerd Bader: Boehringer Ingelheim RCV GmbH & Co KG
Peter Greb: Boehringer Ingelheim RCV GmbH & Co KG
Géraldine Garavel: Boehringer Ingelheim RCV GmbH & Co KG
Emelyne Diers: University of Dundee
Ross McLennan: University of Dundee
Claire Whitworth: University of Dundee
Vesna Vetma: University of Dundee
Klaus Rumpel: Boehringer Ingelheim RCV GmbH & Co KG
Maximilian Scharnweber: Boehringer Ingelheim RCV GmbH & Co KG
Julian E. Fuchs: Boehringer Ingelheim RCV GmbH & Co KG
Thomas Gerstberger: Boehringer Ingelheim RCV GmbH & Co KG
Yunhai Cui: Boehringer Ingelheim Pharma GmbH & Co KG
Gabriela Gremel: Boehringer Ingelheim RCV GmbH & Co KG
Paolo Chetta: Boehringer Ingelheim RCV GmbH & Co KG
Stefan Hopf: Boehringer Ingelheim RCV GmbH & Co KG
Nicole Budano: Boehringer Ingelheim RCV GmbH & Co KG
Joerg Rinnenthal: Boehringer Ingelheim RCV GmbH & Co KG
Gerhard Gmaschitz: Boehringer Ingelheim RCV GmbH & Co KG
Moriz Mayer: Boehringer Ingelheim RCV GmbH & Co KG
Manfred Koegl: Boehringer Ingelheim RCV GmbH & Co KG
Alessio Ciulli: University of Dundee
Harald Weinstabl: Boehringer Ingelheim RCV GmbH & Co KG
William Farnaby: University of Dundee

Nature Communications, 2022, vol. 13, issue 1, 1-15

Abstract: Abstract Targeted protein degradation offers an alternative modality to classical inhibition and holds the promise of addressing previously undruggable targets to provide novel therapeutic options for patients. Heterobifunctional molecules co-recruit a target protein and an E3 ligase, resulting in ubiquitylation and proteosome-dependent degradation of the target. In the clinic, the oral route of administration is the option of choice but has only been achieved so far by CRBN- recruiting bifunctional degrader molecules. We aimed to achieve orally bioavailable molecules that selectively degrade the BAF Chromatin Remodelling complex ATPase SMARCA2 over its closely related paralogue SMARCA4, to allow in vivo evaluation of the synthetic lethality concept of SMARCA2 dependency in SMARCA4-deficient cancers. Here we outline structure- and property-guided approaches that led to orally bioavailable VHL-recruiting degraders. Our tool compound, ACBI2, shows selective degradation of SMARCA2 over SMARCA4 in ex vivo human whole blood assays and in vivo efficacy in SMARCA4-deficient cancer models. This study demonstrates the feasibility for broadening the E3 ligase and physicochemical space that can be utilised for achieving oral efficacy with bifunctional molecules.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-33430-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33430-6

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-33430-6

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33430-6